Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ACTB pseudogene 16 is a processed pseudogene derived from the ACTB (beta-actin) gene, located at one of many dispersed chromosomal loci[7][8]. While its sequence shares strong homology with the functional ACTB gene, it is nonfunctional (i.e., it is not transcribed or translated into an active protein)[8][9]. The presence of many ACTB pseudogenes in the human genome complicates molecular assays such as RT-PCR, because primers may inadvertently bind pseudogene sequences, leading to false or misleading results[1][11]. No known physiological or disease-related role has been documented for ACTB pseudogene 16. Notable considerations: - ACTBP16 is not an active gene, not a therapeutic target, and has no direct role in disease, drug action, or clinical biomarker panels[8][9][12]. - Its identification is mainly relevant in the context of assay design or bioinformatics (primer specificity, genome annotation)[1][11].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ACTB pseudogene 16 (ACTBP16).